Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
Background:
The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT; glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or interferon beta-1b) to once-daily, oral fingolimod. Post hoc analyses evaluated the impact of a switch to fingolimod versus staying on each of the four individual iDMTs.
Methods:
Overall, 1053 patients were randomized 3:1 to switch to fingolimod or remain on iDMT. The primary endpoint was the change in Treatment Satisfaction Quest...
Source: BMC Neurology - November 26, 2014 Category: Neurology Authors: Jonathan CalkwoodBruce CreeHeidi CraytonDaniel KantorBrian SteingoLuigi BarbatoRon HashmonayNeetu AgashivalaKevin McCagueNadia TenenbaumKeith Edwards Source Type: research
Observational Study Assessing Demographic, Economic and Clinical Factors Associated with Access and Utilization of Health Care Services of Patients with Multiple Sclerosis under Treatment with Interferon Beta-1b (EXTAVIA)
by Georgios Hadjigeorgiou, Efthimios Dardiotis, Georgios Tsivgoulis, Triantafyllos Doskas, Damianos Petrou, Nikolaos Makris, Nikolaos Vlaikidis, Thomas Thomaidis, Athanasios Kyritsis, Nikolaos Fakas, Xoulietta Treska, Clementine Karageorgiou, Stefania Sotirli, Christos Giannoulis, Dimitra Papadimitriou, Ioannis Mylonas, Evaggelos Kouremenos, Georgios Vlachos, Dimitrios Georgiopoulos, Despoina Mademtzoglou, Michalis Vikelis, Elias Zintzaras
Multiple sclerosis (MS) results in an extensive use of the health care system, even within the first years of diagnosis. The effectiveness and accessibility of the health care system ma...
Source: PLoS One - November 24, 2014 Category: Biomedical Science Authors: Georgios Hadjigeorgiou et al. Source Type: research
Treatment of Mood Disorders in Multiple Sclerosis
Opinion statement
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with a significant comorbidity with depressive disorders. Prevalence rates for major depressive disorder (MDD) range from 36 % to 54 % and the rate is around 22 % for adjustment disorders. Selective serotonin reuptake inhibitors (SSRIs) are considered well-tolerated first-line treatment. Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are generally reserved for second-line use after SSRIs, because of sedating or anticholinergic side effects. SNRIs, with the exception of...
Source: Current Treatment Options in Neurology - November 5, 2014 Category: Neurology Source Type: research
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome
The BEtaferon®/BEtaseron® in Newly Emerging MS For Initial Treatment (BENEFIT) trial assessed the efficacy of early versus delayed treatment with interferon beta-1b for patients with clinically isolated syndrome (CIS). Patients were randomly assigned to receive either interferon beta-1b 250 μg every other day (early treatment, n = 292) or placebo (delayed treatment, n = 176) for 2 years or until progression to clinically definite multiple sclerosis. Clinical and magnetic resonance imaging (MRI) outcomes were assessed after 2 years (at the end of the placebo-controlled phase) and then again at 3, 5, and 8 years p...
Source: Therapeutic Advances in Neurological Disorders - November 2, 2014 Category: Neurology Authors: Freedman, M. S. Tags: Review Source Type: research
The Long-Term Value of Glatiramer Acetate for the Treatment of Relapsing Remitting Multiple Sclerosis in the Netherlands
To evaluate the cost-effectiveness of glatiramer acetate (Copaxone®) as a disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) compared to intravenous [natalizumab (Tysabri®), alemtuzumab (Lemtrada®) ] or subcutaneous injectables [interferon-beta-1b (Betaferon®), interferon-beta-1a 44mcg, 22mcg, 30mcg (Rebif-44®, Rebif-22®, Avonex®) ] and oral DMTs [fingolimod (Gilenya®), dimethyl fumarate (Tecfidera®), teriflunomide (Aubagio®) ]. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J.L. Purchase, L.E. Wilson, A. Prüfert Source Type: research
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
Conclusions
These 8-year results provide further evidence supporting early initiation of treatment with IFNB1b in patients with a first event suggestive of MS. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 17, 2014 Category: Neurosurgery Authors: Edan, G., Kappos, L., Montalban, X., Polman, C. H., Freedman, M. S., Hartung, H.-P., Miller, D., Barkhof, F., Herrmann, J., Lanius, V., Stemper, B., Pohl, C., Sandbrink, R., Pleimes, D., for the BENEFIT Study Group Tags: JNNP Patients' choice, Open access, Immunology (including allergy), Multiple sclerosis Source Type: research
BENEFIT 8-year results provide further support for the long-term value of early treatment of multiple sclerosis
Interferon-β-1b therapy started at CIS continued to alleviate risk of clinically definite MS and inhibit cognitive decline after 8 years. Clinically isolated syndrome (CIS) is the first clinical event suggestive of multiple sclerosis (MS). Early treatment is advocated in MS since active demyelination and axonal damage are most extensive in the early stages.1 Beyond the threshold of compensation, neuronal loss causes irreversible functional disability. Moreover, over 80% of CIS cases with MS-consistent brain lesions at presentation will eventually convert to clinically definite MS (CDMS) in the natural history.2 E...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 17, 2014 Category: Neurosurgery Authors: Fujihara, K. Tags: Immunology (including allergy), Multiple sclerosis, Neuroimaging, Memory disorders (psychiatry) Editorial commentaries Source Type: research
Interaction of interferon beta-1b and CXCR4 on T cells in multiple sclerosis
Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS). A key event of its pathology is the infiltration of activated leukocytes into the CNS. Interferon-beta (IFN beta) is an effective MS treatment, which might have influence on leukocytes infiltration. However, little is known about the molecular mechanisms mediated by IFN beta. In vitro application of IFN beta-1b reduced the CXCL12-mediated leukocyte migration. This CXCL12-dependent signalling acts via its receptor CXCR4 resulting in cell chemotaxis. (Source: Journal of Neuroimmunology)
Source: Journal of Neuroimmunology - October 15, 2014 Category: Allergy & Immunology Authors: , Viktoria Gudi, J.A. Lindquist, Sabine Lindquist, Martin Stangel Tags: 109 Source Type: research
Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis.
Abstract
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS. Here we review the clinica...
Source: Advances in Therapy - September 3, 2014 Category: Drugs & Pharmacology Authors: Marziniak M, Meuth S Tags: Adv Ther Source Type: research
Effect of Arginine on Pre-nucleus Stage of Interferon Beta-1b Aggregation.
Abstract
Understanding the mechanism of aggregation of a therapeutic protein would not only ease the manufacturing processing but could also lead to a more stable finished product. Aggregation of recombinant interferon (IFNβ-1b) was studied by heating, oxidizing, or seeding of unformulated monomeric solution. The formation of aggregates was monitored by dynamic light scattering (DLS) and UV spectroscopy. The autocatalytic monomer loss model was used to fit the data on aggregation rates. The influence of pre-nucleation on aggregation step was demonstrated by inducing the liquid samples containing a monomer...
Source: AAPS PharmSciTech - August 21, 2014 Category: Drugs & Pharmacology Authors: Fazeli A, Haji-Abdolvahab M, Shojaosadati SA, Schellekens H, Khalifeh K, Moosavi-Movahedi AA, Fazeli MR Tags: AAPS PharmSciTech Source Type: research
Melatonin Acts as Antioxidant and Improves Sleep in MS Patients.
Abstract
The relationship between the prevalence of multiple sclerosis (MS) and sunlight's ultraviolet radiation was proved. Oxidative stress plays a role in the pathogenic traits of MS. Melatonin possesses antioxidative properties and regulates circadian rhythms. Sleep disturbances in MS patients are common and contribute to daytime fatigue. The aim of study was to evaluate 5 mg daily melatonin supplementation over 90 days on serum total oxidant status (TOS), total antioxidant capacity (TAC) and its influence on sleep quality and depression level of MS patients. A case-control prospective study was perf...
Source: Neurochemical Research - June 30, 2014 Category: Neuroscience Authors: Adamczyk-Sowa M, Pierzchala K, Sowa P, Mucha S, Sadowska-Bartosz I, Adamczyk J, Hartel M Tags: Neurochem Res Source Type: research
The Effects of Dodecyl Maltoside and Sodium Dodecyl Sulfate Surfactants on the Stability and Aggregation of Recombinant Interferon Beta-1b
Journal of Interferon & Cytokine Research , Vol. 0, No. 0. (Source: Journal of Interferon)
Source: Journal of Interferon - June 23, 2014 Category: Research Tags: article Source Type: research
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial
Conclusions: Different types of DMTs may improve some aspects of cognitive function in patients with MS. Treatment with Avonex and Rebif (Interferon beta-1a preparations) were more helpful in resolving the cognitive impairments in MS patients compared to Betaferon (Interferon beta-1b) as investigated in this study. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - May 19, 2014 Category: Neurology Authors: Naghmeh Mokhber, Amir Azarpazhooh, Elias Orouji, Stephen M. Rao, Bita Khorram, Mohammad Ali Sahraian, Mohsen Foroghipoor, Morteza Modares Gharavi, Sorayya Kakhi, Karim Nikkhah, Mahmoud Reza Azarpazhooh Tags: Original Articles Source Type: research
HLA Genes and Interferon-beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis (P1.213)
CONCLUSIONS: The interferon-beta preparation still remains the single most significant determinant for the risk of developing NAbs in MS. HLA allele group carriage influences the risk of NAbs differently within interferon-beta-1a and interferon-beta-1b treated MS patients.Disclosure: Dr. Fink has received personal compensation for activities with Novartis. Ms. Link has received research support from Karolinska Institute. Ms. Lundkvist has received research support from Biogen Idec. Dr. Hermanrud has nothing to disclose. Dr. Lima has nothing to disclose. Dr. Brynedal has received research support from the Swedish Research C...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Fink, K., Link, J., Lundkvist, M., Hermanrud, C., Lima, I., Brynedal, B., Kockum, I., Hillert, J., Fogdell-Hahn, A. Tags: MS and CNS Inflammatory Disease: Treatment Mechanisms of Action Source Type: research
Mismatch Negativity Links to Information Processing in Multiple Sclerosis (MS) (P4.165)
CONCLUSIONS: Compared to matched controls, MS participants had blunted MMN which was associated with impaired SDMT performance. MMN may serve as a biomarker of cognitive impairment in MS. Disclosure: Dr. Jackson has nothing to disclose. Dr. Charvet has received personal compensation for activities with Biogen Idec as a consultant. Dr. Charvet holds stock and/or stock options in Johnson & Johnson. Dr. Amella has nothing to disclose. Dr. Proudfit has nothing to disclose. Dr. Krupp has received personal compensation for activities with Teva Neurosciences, Biogen Idec, EMD Serono, Betaseron/Bayer Healthcare Pharmaceutic...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Jackson, F., Charvet, L., Amella, M., Proudfit, G., Krupp, L. Tags: Cognition in Multiple Sclerosis Source Type: research
